[Featured Stock] IMBDX, US FDA Approves Enhertu as World's First Tumor-Agnostic Cancer Treatment... Collaboration Spotlighted↑

IMBDX is showing strong performance. This is interpreted as being influenced by the news that the U.S. Food and Drug Administration (FDA) approved the antibody-drug conjugate (ADC) anticancer drug 'Enhertu,' jointly developed by Daiichi Sankyo and AstraZeneca, as a treatment for all solid tumors.

As of 1:56 PM on the 17th, IMBDX is trading at 16,770 KRW, up 3.14% compared to the previous day.

According to industry sources, the U.S. FDA recently granted accelerated approval for Enhertu as a treatment for HER2-positive solid tumors. Enhertu is an antibody-drug conjugate anticancer drug jointly developed by Daiichi Sankyo and AstraZeneca.

Enhertu's efficacy was confirmed in three multicenter Phase 2 clinical studies. Enhertu's sales last year reached $2.57 billion (approximately 3.6 trillion KRW), more than doubling compared to the previous year ($1.25 billion, approximately 1.73 trillion KRW).

Meanwhile, IMBDX signed a Phase 2 partnership agreement with AstraZeneca in March last year for companion diagnostics for prostate cancer treatment.